With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

Catalyst Pharmaceuticals targets a $1B+ LEMS market as FIRDAPSE grows 15–20% and AGAMREE scales in DMD. Learn more about CPRX stock here.

The NDA is supported by data from part A of the phase 2 PROSPECT trial, which evaluated tirabrutinib in 48 adult patients with R/R PCNSL.

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective ...

NG Biotech manufactured the assays in France, with Hardy Diagnostics serving as the exclusive distributor in the US.

The company said Tuesday that the FDA greenlit a supplemental new drug application for Wakix, a treatment for cataplexy, a narcolepsy symptom characterized by sudden muscle weakness, in pediatric ...

Under the terms of a settlement and license agreement with Regeneron, Samsung Bioepis will be able to launch Opuviz in the ...

Treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I under review.

Discover how Elon Musk's Neuralink brain chip works, its groundbreaking applications for paralysis, and the future of mind-controlled technology.

Personalized Gene Editing Saves Baby in Record Time In early 2025, researchers successfully treated a baby boy with a rare, ...

Elon Musk's Neuralink has captured the public’s attention and imagination with its futuristic vision of connecting the human brain to computers. Neuralink has drawn interest to the brain computer ...

On Wednesday, Musk's brain-implant company said that it now has 21 participants enrolled in clinical trials across the globe. This marks a notable increase from the 12 people reported using the ...